- Research note
- Open Access
Donor variability may mask dimethyl fumarate’s effects on nuclear factor E2-related factor 2 in human peripheral blood mononuclear cells
BMC Research Notes volume 10, Article number: 553 (2017)
Dimethyl fumarate (DMF) is an anti-inflammatory and antioxidant drug used to treat multiple sclerosis, but its mechanism(s) of action are not fully understood. In central nervous system (CNS) cells, DMF activates nuclear factor E2-related factor 2 (Nrf2), perhaps ameliorating oxidative stress-induced damage. However, it is not known whether DMF also activates Nrf2 in peripheral immune cells, which are known to participate in CNS demyelination. We conducted a single observation study to determine whether DMF can activate Nrf2 in peripheral immune cells in vitro.
We performed enzyme-linked immunosorbent assays to measure Nrf2 activation in nuclear extracts of human peripheral blood mononuclear cells treated with DMF at time points from 0 to 6 h, initially determining that DMF did not activate Nrf2, and that the mechanism(s) of action of DMF may thus differ in the periphery compared to the CNS. However, further analyses of our data suggest that high Tmax variability is masking Nrf2 activation in individual donors. Additionally, there may be sub-populations of responders, perhaps related to genetic polymorphisms in Nrf2.
Dimethyl fumarate (DMF) is an anti-inflammatory and antioxidant drug approved for the treatment of relapsing–remitting multiple sclerosis (MS). Treatment with DMF leads to significant reductions in relapse rates, progression of disability, and active brain lesions . The mechanisms of action (MOA) of DMF are not entirely understood, but are believed to involve therapeutic effects on immune dysregulation and oxidative stress that lead to the pathology of MS. Nuclear factor E2-related factor 2 (Nrf2) is the principal regulator of the phase II cellular antioxidant response, and there is extensive evidence that DMF alters Nrf2 expression and activation in vitro in central nervous system (CNS) cells .
While MS is a neuro-inflammatory disease, MS likely begins with the peripheral immune system inappropriately activated in response to an environmental antigen, and pathogenesis is immune cell mediated [3, 4]. Peripheral immune cells, including monocytes which migrate into the CNS to become macrophages, contribute to disease progression. Active MS lesions are infiltrated by large numbers of peripherally derived-macrophages that contain myelin debris, indicating that they are responsible for demyelination [5,6,7]. Taken together, we hypothesize that given its efficacy in reducing active brain lesions, orally administered DMF is likely to have an MOA that includes effects on peripherally-derived macrophages, and that it involves activation of Nrf2. However, direct evidence that DMF acts via Nrf2 in peripheral immune cells is, to our knowledge, absent. Herein, we conducted a single observation study to determine whether DMF can activate Nrf2 in peripheral blood mononuclear cells (PBMCs).
Materials and methods
Cell stimulation and sample processing
Apheresis products were purchased from KeyBiologics (Memphis, TN). The company followed IRB regulations for consenting of human donors. PBMCs were isolated and cryopreserved as previously described . PBMCs were quick thawed and washed in RPMI (Gibco by Thermo Fisher, Waltham, MA) prior to manual counting with Trypan Blue (Sigma-Aldrich, St. Louis, MO) viability assessment. At least 3.2 × 106 viable cells were used per treatment. In initial time-course experiments, cells were resuspended in serum-free RPMI, then left untreated, treated with vehicle (ethanol), or treated with 200 µg/ml DMF (Sigma-Aldrich, St. Louis, MO) for 30 min to 6 h at 37 °C/5% CO2. Nuclear extraction was performed according to TransAM Nrf2 kit protocol (Active Motif, Carlsbad, CA). Protein concentration for each sample was determined using a bicinchoninic acid (BCA) assay kit, according to manufacturer’s protocol (Pierce, Rockford, IL).
In a second set of experiments, we used a commercial nuclear extraction kit according to manufacturer’s protocol (Cayman Chemical, Ann Arbor, MI), added 2.5% FBS (final concentration; Gibco, Waltham, MA) to the samples 15 min after DMF addition in order to improve cell survival (also added to UNT and VEH), reduced the number of incubation time points to 2 and 4 h (those most likely to show activation based on literature), and added UNT controls for both time points (formerly untreated samples were representative of the longest time point in each assay).
Enzyme-linked immunosorbent assays (ELISAs)
To measure Nrf2 activation, we used the TransAM Nrf2 kit, a plate based ELISA kit on which oligonucleotide containing the ARE (antioxidant response element) consensus binding site has been immobilized. The active form of Nrf2 binds to this site, and the detection antibody recognizes an epitope on Nrf2 upon DNA binding. Five micrograms of nuclear extract per sample was assayed. Positive control was Nrf2-transfected COS-7 nuclear extract. Assays were performed according to manufacturer’s protocols in duplicate or triplicate, and plates were read using a SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA).
To measure cyclic AMP (cAMP) production as a test of DMF efficacy, 2 × 106 viable PBMCs (per treatment) were treated for 5 min with 50, 100 and 200 µg/ml of DMF, or treated with 5 µl of vehicle control (ethanol, volume equal to 200 µg/ml DMF dose). Samples were processed and cAMP assay performed according to manufacturer’s protocol (Enzo Life Sciences, Farmingdale, NY).
Data and statistical analyses
Values for each donor were determined as an average of the replicates, which were generated from internal 4 parameter logistic standard curves using Softmax software (Molecular Devices) for cAMP assays, or absorbance at 450 nm for Nrf2 assays. These values were used to determine the arithmetic mean, plus or minus the standard error of the mean, of each condition. Treatments and controls were tested for significant differences in Microsoft Excel 2010 using one-way ANOVAs and Student’s t-tests.
Treatment of PBMCs with DMF did not appear to result in Nrf2 activation (Fig. 1a). To ensure that the DMF stocks we were using were active, we performed parallel experiments where PBMCs from the same donor were treated with varying concentrations of DMF for cAMP and Nrf2 assays. We previously demonstrated that DMF stimulates cAMP production in PBMCs . Here, DMF stimulated cAMP production in a similar manner (Fig. 1b, left panel), but did not appear to activate Nrf2 in this donor (Fig. 1b, right panel).
In order to eliminate technical difficulties as the reason for failure to achieve Nrf2 activation, we analyzed cell survival post-treatment and added varying concentrations of FBS to optimize survival. UNT and DMF treated samples did not differ significantly in their survival regardless of FBS presence or concentration, but 2.5% FBS resulted in slightly higher survival for both compared to serum-free RPMI at 2 and 4 h (data not shown). We also varied the amount of protein used in ELISAs (1–10 µg, the max recommended), and attempted stimulation with monomethyl fumarate (active metabolite of DMF). None of these conditions resulted in consistent Nrf2 activation (data not shown).
Finally, to eliminate our extraction method as the reason for our results, we switched to a commercial nuclear extraction kit and repeated ELISAs at 2 and 4 h plus 2.5% FBS (Fig. 1c). These data appeared to confirm that Nrf2 is not activated by DMF in human PBMCs. However, when we analyzed our data set as a whole, including all donors from both our initial time courses (1a) and our optimized time courses (1c), we noticed that several donors showed an elevation in Nrf2, but there was high variability in the time point at which the stimulation occurred (Tmax, Table 1). We thus decided to compare UNT values versus maximum Nrf2 assay values (Cmax), regardless of time point (Fig. 2a). In the analysis, the difference in Nrf2 activation between UNT and DMF treated cells was significant (p < 0.05), so it is possible that Nrf2 is being stimulated by DMF, just with a highly variable time course. It should be noted that for three of the donors Cmax were UNT values, meaning they exhibited no Nrf2 stimulation at any time point. Continuing our examination of individual donor responses, we observed three distinct patterns; in “non-responders,” Nrf2 is slightly decreased with DMF treatment, in “moderate responders,” Nrf2 is increased modestly at 2 h but drops below UNT by 4 h, and in “sustained responders,” Nrf2 is robustly activated at 2 h, and remains above UNT at 4 h (Fig. 2b, c). Within our combined data set, we had one donor that was analyzed in experiments for both Fig. 1a and c, meaning that we could compare whether donor response type is consistent. Figure 2d indicates that this donor, who appeared to be a sustained responder in our initial experiments, responded in the same manner in our optimized time courses.
The MOA(s) of DMF are still under investigation, but activation of Nrf2 and its downstream effectors in the CNS and periphery has been a primary focus. Recently however, DMF treatment was shown to be equally protective in the mouse model of MS in wild type and Nrf2−/− mice, and protection was associated with changes in T cell, monocyte and B-cell phenotypes, raising the possibility that Nrf2 is not essential for DMFs therapeutic actions on peripheral immune cells . Studies of DMF treated patients also show alterations in the phenotypes and ratios of these cell types [10,11,12]. In apparent contrast to these data, Gopal et al. published a paper using PBMCs entitled, “Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate”, however, this study did not directly examine activation of Nrf2, but rather examined induction of downstream targets NAD(P)H quinone dehydrogenase-1 (NQO1) and heme-oxygenase-1 (HO-1) at time points from 0 to 4 h .
In addition to its widely reported activation of Nrf2 in CNS cells, in vitro DMF treatment of peripheral immune cells has been shown to affect NF-κB activation and production of a variety of inflammatory mediators; we have previously demonstrated that DMF stimulates production of the immunomodulator cAMP via the prostaglandin E2 receptor in PBMCs, but only at relatively high concentrations of DMF [2, 8]. It is possible that the MOA of DMF is primarily dependent on activating Nrf2 in the CNS to ameliorate oxidative stress, while its MOA in the periphery involves other immunomodulatory pathways, some of which may have effectors in common with the Nrf2 pathway; the aforementioned HO-1, for example, which can be induced by both cAMP and Nrf2-dependent pathways [13,14,15]. Of particular interest in this case, Gopal’s above mentioned study showed induction of HO-1 only at high concentrations of DMF, very similar to the pattern of cAMP induction we previously demonstrated and present as control data in Fig. 1b [8, 13]. cAMP is not the sole mediator of DMF’s therapeutic efficacy in the periphery, but we present it as a potential part of the MOA of DMF in MS, which may be either Nrf2-independent or additive/synergistic with Nrf2.
Our individual donor analyses suggest that DMF activation of Nrf2 in PBMCs is highly variable—with subgroups of responders that when aggregated across a time course mask activation. This kind of variability is to be expected in clinical trials since there are many factors in how an oral drug is taken up by patients, but is less expected in in vitro studies. These differences may be due to single nucleotide polymorphisms (SNPs) in Nrf2. There are at least nine (SNPs) in humans; two are in the promoter region of Nrf2 and reduce transcriptional activity. These latter two plus one additional SNP have been associated with variable Nrf2 response to caffeine . Another possibility is that there are differences in the distribution of the PBMC sub-populations between donors that affect responses due to differential cell type responses. It is interesting to note that sustained responders have significantly lower UNT values than moderate responders (and comparison to non-responder UNT is near significance at p = 0.058, Fig. 2b), and in fact the “robust activation” seen in sustained responders simply brings their Nrf2 activation levels near the UNT levels in the other two groups. The biological/clinical meaning of this difference is unknown.
In future studies, it would be of interest to determine whether specific SNPs are associated with Nrf2 response in PBMCs. If effects on peripheral immune cells are part of the MOA of DMF, determining Nrf2 genotype might be a tool to help decide who should take the drug, which is extremely expensive and has the rare (but serious) side effect of progressive multifocal leukoencephalopathy .
There were a number of limitations to this study. The DMF concentration used is relatively high, and addition of a cell type in which DMF is known to activate Nrf2 as a positive control would have strengthened this study. Also, although DMF activates Nrf2 in other cell types within the time points we examined, it is possible that in the “non-responders,” activation is either quickly transient or delayed beyond 6 h in PBMCs. Also, though cell viability was good, the slight drops seen at 2 h (non-responders) and 4 h (non and moderate responders) may contribute to the small reduction in Nrf2 activation compared to UNT. The small sample size for our proposed subgroups makes these results far more indicative than conclusive, though it provides an interesting avenue for analyzing future experiments involving DMF responses. Finally, only healthy control cells were utilized in these studies—it will be very important to compare how cells from MS patients respond in future studies.
antioxidant response element
central nervous system
enzyme-linked immunosorbent assay
fetal bovine serum
mechanism of action
nuclear factor kappa B
NAD(P)H quinone dehydrogenase 1
nuclear factor E2-related factor 2
peripheral blood mononuclear cell
single nucleotide polymorphism
Bomprezzi R. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord. 2015;8:20–30.
Gill AJ, Kolson DL. Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol. 2013;33:307–59.
Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S. Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol. 2015;28:206–19.
Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005;26:485–95.
Dittel BN. CD4 T cells: balancing the coming and going of autoimmune-mediated inflammation in the CNS. Brain Behav Immun. 2008;22:421–30.
Grigoriadis N, van Pesch V. A basic overview of multiple sclerosis immunopathology. Eur J Neurol. 2015;22(Suppl 2):3–13.
Dogan RN, Karpus WJ. Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation. Front Biosci. 2004;9:1500–5.
Fiedler SE, Kerns AR, Tsang C, Tsang V, Bourdette D, Salinthone S. Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2016;475:19–24.
Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM, Shetty A, Sagan SA, Cree BA, Sobel RA, Wipke BT, Steinman L, et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci USA. 2016;113:4777–82.
Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A. Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis. J Immunol. 2017;198:691–8.
EE Longbrake, MJ Ramsbottom, C Cantoni, L Ghezzi, AH Cross, L Piccio. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler 2016;22(8):1061–70.
Michell-Robinson MA, Moore CS, Healy LM, Osso LA, Zorko N, Grouza V, Touil H, Poliquin-Lasnier L, Trudelle AM, Giacomini PS, et al. Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis. Ann Clin Transl Neurol. 2016;3:27–41.
Gopal S, Mikulskis A, Gold R, Fox RJ, Dawson KT, Amaravadi L. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the phase 3 DEFINE and CONFIRM studies. Mult Scler. 2017. https://doi.org/10.1177/1352458517690617.
Durante W, Christodoulides N, Cheng K, Peyton KJ, Sunahara RK, Schafer AI. cAMP induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle. Am J Physiol. 1997;273:H317–23.
Kronke G, Bochkov VN, Huber J, Gruber F, Bluml S, Furnkranz A, Kadl A, Binder BR, Leitinger N. Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein. J Biol Chem. 2003;278:51006–14.
Boettler U, Volz N, Teller N, Haupt LM, Bakuradze T, Eisenbrand G, Bytof G, Lantz I, Griffiths LR, Marko D. Induction of antioxidative Nrf2 gene transcription by coffee in humans: depending on genotype? Mol Biol Rep. 2012;39:7155–62.
Nieuwkamp DJ, Murk JL, van Oosten BW. PML in patients treated with dimethyl fumarate. N Engl J Med. 2015;373:584.
ARK, CT and HNL performed experiments, SEF analyzed data and wrote manuscript, SS designed project and revised manuscript. All authors read and approved the final manuscript.
The authors declare that there are no competing interests.
Availability of data and materials
All data generated or analyzed during this study are included in this published article (and its Additional file 1).
Consent for publication
Ethics approval and consent to participate
The apheresis products used in this study were purchased from KeyBiologics (Memphis, TN), collected under Quorum IRB Committee Protocol: KEY-010-001. Quorum is an AAHRPP (Association for the Accreditation of Human Research Protection Programs) accredited independent review board, licensed to approve a study involving humans. All procedures performed involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed, written consent was obtained from all individual participants included in the study. These studies were also approved by the Subcommittee on Research Safety and the Research and Development Committee at the VA Portland Health Care System.
This work was supported by a Biomedical Laboratory Research and Development Service Merit Review (1I01BX001793), from the United States Department of Veterans Affairs. Sponsor had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, nor in the decision to submit the article for publication.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Fiedler, S.E., Kerns, A.R., Tsang, C. et al. Donor variability may mask dimethyl fumarate’s effects on nuclear factor E2-related factor 2 in human peripheral blood mononuclear cells. BMC Res Notes 10, 553 (2017). https://doi.org/10.1186/s13104-017-2862-8
- Dimethyl fumarate
- Peripheral blood mononuclear cell
- Cyclic AMP